Multidrug efflux pumps in Staphylococcus aureus: an update. by Costa, SS et al.
Send Orders of Reprints at reprints@benthamscience.net 
 The Open Microbiology Journal, 2013, 7, (Suppl 1-M5) 59-71 59 
 
 1874-2858/13 2013 Bentham Open 
Open Access 
Multidrug Efflux Pumps in Staphylococcus aureus: an Update 
Sofia Santos Costa1,2, Miguel Viveiros1,3, Leonard Amaral1,3 and Isabel Couto1,2,* 
1Grupo de Micobactérias, Unidade de Microbiologia Médica, Instituto de Higiene e Medicina Tropical, Universidade 
Nova de Lisboa (IHMT, UNL), Portugal 
2Centro de Recursos Microbiológicos (CREM), UNL, Portugal 
3COST ACTION BM0701 (ATENS), Brussels, Belgium 
Abstract: The emergence of infections caused by multi- or pan-resistant bacteria in the hospital or in the community set-
tings is an increasing health concern. Albeit there is no single resistance mechanism behind multiresistance, multidrug ef-
flux pumps, proteins that cells use to detoxify from noxious compounds, seem to play a key role in the emergence of these 
multidrug resistant (MDR) bacteria. During the last decades, experimental data has established their contribution to low 
level resistance to antimicrobials in bacteria and their potential role in the appearance of MDR phenotypes, by the extru-
sion of multiple, unrelated compounds. Recent studies suggest that efflux pumps may be used by the cell as a first-line de-
fense mechanism, avoiding the drug to reach lethal concentrations, until a stable, more efficient alteration occurs, that al-
lows survival in the presence of that agent.  
In this paper we review the current knowledge on MDR efflux pumps and their intricate regulatory network in Staphylo-
coccus aureus, a major pathogen, responsible from mild to life-threatening infections. Particular emphasis will be given to 
the potential role that S. aureus MDR efflux pumps, either chromosomal or plasmid-encoded, have on resistance towards 
different antimicrobial agents and on the selection of drug - resistant strains. We will also discuss the many questions that 
still remain on the role of each specific efflux pump and the need to establish appropriate methodological approaches to 
address all these questions.  
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1. INTRODUCTION 
 The introduction of antibiotics for the treatment of infec-
tious diseases was one of the hallmarks in the 20th century 
medicine. However, shortly after their introduction into the 
clinical practice, the first bacteria showing antibiotic resis-
tance were described. Since then, the development of new 
antibiotics has been accompanied by the steady increase of 
antibiotic-resistant bacterial strains and the diversity of 
mechanisms used by bacteria to surpass the lethal effect of 
these compounds. Nowadays, at least one mechanism of re-
sistance is described for each class of commonly used anti-
biotics [1]. Moreover, many bacterial species show multi- or 
pan-resistant phenotypes. Many of these multidrug resistant 
(MDR) bacteria can cause life-threatening infections, being a 
major concern both in the hospital and the community [2, 3]. 
Staphylococcus aureus, a Gram-positive cocci is one of the 
major bacterial pathogens, causing mild to life-threatening 
infections [4]. Besides its potential virulence, S. aureus also 
shows a remarkable diversity of resistance mechanisms to-
wards antimicrobial agents [5]. Of major concern are the  
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methicillin-resistant S. aureus (MRSA) strains, resistant to 
all beta-lactam antibiotics, which for many years caused ma-
jor outbreaks in nosocomial environments and that are now 
increasingly isolated from the community, where they may 
also cause severe, many times fatal infections [6]. 
 Bacteria can use different mechanisms of resistance to 
antibiotics, which include degradation or modification of the 
antibiotic; alteration of the bacterial target of the antibiotic; 
target protection and reduction of the intracellular concentra-
tion of the antibiotic, either by a decreased permeability of 
the cell wall or by the efflux of the antibiotic from the cell. 
Efflux-mediated resistance has been overshadowed in con-
trast with the other mechanisms known. However, it has 
been gathering more interest, as we recognize that many bac-
terial efflux pumps are able to extrude several, unrelated 
classes of antimicrobial compounds from the cell, promoting 
the appearance of multidrug resistance phenotypes [7, 8].  
 The physiological role of efflux pumps in bacteria has 
been related to the elimination of endogenous metabolites 
that are noxious to the cell, the secretion of virulence deter-
minants, and in cell stress responses, suggesting that the 
drugs are “accidental substrates” of these transporters [9, 
10]. 
 Bacterial efflux systems can be either specific, extruding 
only one antibiotic or class of antibiotics, or be capable of 
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extruding several classes of antimicrobial compounds, being 
designated multidrug resistance efflux pumps. These MDR 
efflux systems are classified in five families according to 
their energy requirements and structure namely, the major 
facilitator superfamily (MFS); the small multidrug resistance 
(SMR) family; the multidrug and toxic compound extrusion 
(MATE) family; the resistance-nodulation-cell division 
(RND) superfamily; and the adenosine-triphosphate (ATP)-
binding cassette (ABC) superfamily. The transporters of the 
first four families are secondary transporters that use the 
proton motive force to drive the extrusion of their substrates 
by an antiport H+:drug mechanism, with the exception of the 
MATE family, which can also use the sodium membrane 
gradient as the source of energy. On the other hand, the 
transporters of the ABC superfamily are primary transporters 
that use ATP to drive the extrusion of their substrates [11]. 
 To date, more than ten multidrug efflux pumps have been 
described for S. aureus, encoded either in the chromosome 
or in plasmids (Table 1). This review summarizes the most 
recent data on S. aureus multidrug efflux pumps, focusing on 
their contribution to antimicrobial resistance of S. aureus 
strains.  
2. CHROMOSOMALLY-ENCODED MDR EFFLUX 
PUMPS 
2.1. NorA 
 The multidrug efflux pump NorA is one of the most stud-
ied efflux systems in S. aureus. The chromosomal gene that 
Table 1. Multidrug Efflux Pumps Described for Staphylococcus aureus 
Efflux Pump Familya Regulator(s)b Substrate Specificity References 
Chromosomally-encoded Efflux Systems 
NorA MFS MgrA, NorG(?) 
Hydrophilic fluoroquinolones (ciprofloxacin, norfloxacin) 
QACs (tetraphenylphosphonium, benzalkonium chloride)  
Dyes (e.g. ethidium bromide, rhodamine) 
[16,18,19] 
NorB MFS MgrA, NorG 
Fluoroquinolones (e.g. hydrophilic: ciprofloxacin, norfloxacin and hydrophobic: 
moxifloxacin, sparfloxacin) 
Tetracycline 
QACs (e.g. tetraphenylphosphonium, cetrimide) 
Dyes (e.g. ethidium bromide) 
[31] 
NorC MFS MgrA(?), NorG 
Fluoroquinolones (e.g. hydrophilic: ciprofloxacin and hydrophobic: moxifloxacin) 
Dyes (e.g. rhodamine) 
[35,36] 
MepA MATE MepR 
Fluoroquinolones (e.g. hydrophilic: ciprofloxacin, norfloxacin and hydrophobic: 
moxifloxacin, sparfloxacin) 
Glycylcyclines (e.g. tigecycline) 
QACs (e.g. tetraphenylphosphonium, cetrimide, benzalkonium chloride)  
Dyes (e.g. ethidium bromide) 
[37,38] 
MdeA MFS n.i. 
Hydrophilic fluoroquinolones (e.g. ciprofloxacin, norfloxacin) 
Virginiamycin, novobiocin, mupirocin, fusidic acid 
QACs (e.g. tetraphenylphosphonium, benzalkonium chloride, dequalinium)  
Dyes (e.g. ethidium bromide) 
[39,40] 
SepA n.d. n.i. 
QACs (e.g. benzalkonium chloride) 
Biguanidines (e.g. chlorhexidine) 
Dyes (e.g. acriflavine) 
[41] 
SdrM MFS n.i. 
Hydrophilic fluoroquinolones (e.g. norfloxacin) 
Dyes (e.g. ethidium bromide, acriflavine) 
[42] 
LmrS MFS n.i. 
Oxazolidinone (linezolid) 
Phenicols (e.g. choramphenicol, florfenicol) 
Trimethoprim, erythromycin, kanamycin, fusidic acid 
QACs (e.g. tetraphenylphosphonium) 
Detergents (e.g. sodium docecyl sulphate) 
Dyes (e.g. ethidium bromide) 
[43] 
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Table 1. Contd….. 
Efflux Pump Familya Regulator(s)b Substrate Specificity References 
Plasmid-encoded Efflux Systems 
QacA MFS QacR 
QACs (e.g. tetraphenylphosphonium, benzalkonium chloride, dequalinium) 
Biguanidines (e.g. chlorhexidine) 
Diamidines (e.g. pentamidine) 
Dyes (e.g. ethidium bromide, rhodamine, acriflavine) 
[45,49] 
QacB MFS QacR 
QACs (e.g. tetraphenylphosphonium, benzalkonium chloride) 
Dyes (e.g. ethidium bromide, rhodamine, acriflavine) 
[53] 
Smr SMR n.i. 
QACs (e.g. benzalkonium chloride, cetrimide) 
Dyes (e.g. ethidium bromide) 
[58,61] 
QacG SMR n.i. 
QACs (e.g. benzalkonium chloride, cetyltrymethylammonium) 
Dyes (e.g. ethidium bromide) 
[67] 
QacH SMR n.i. 
QACs (e.g. benzalkonium chloride, cetyltrymethylammonium) 
Dyes (e.g. ethidium bromide) 
[68] 
QacJ SMR n.i. 
QACs (e.g. benzalkonium chloride, cetyltrymethylammonium) 
Dyes (e.g. ethidium bromide) 
[69] 
a n.d.: The family of transporters to which SepA belongs is not elucidated to date. 
b n.i.: The transporter has no regulator identified to date. 
QACs: quaternary ammonium compounds 
codes for it, norA, was first described in a fluoroquinolone-
resistant isolate collected in 1986 at a Japanese hospital [12]. 
The norA gene presents some genetic diversity, with three 
norA alleles described to date that differ up to 10% in the 
nucleotide sequence [13-15]. NorA is a 388 aminoacid pro-
tein that comprises 12 transmembrane segments, belongs to 
the MFS and shares 44% identity with the multidrug efflux 
pump Bmr from Bacillus subtilis and 24% identity with the 
tetracycline efflux pump Tet(A) from Escherichia coli 
[16,17]. Several studies have shown that NorA can extrude 
an array of chemically and structurally dissimilar com-
pounds, namely hydrophilic fluoroquinolones, such as nor-
floxacin and ciprofloxacin, dyes, like ethidium bromide and 
biocides, such as quaternary ammonium compounds 
[16,18,19]. It is known that norA has a basal level of expres-
sion, which accounts for some level of reduced susceptibility 
towards these antimicrobial compounds [19,20]. Increased 
resistance to fluoroquinolones, biocides and dyes has been 
associated with NorA-mediated efflux, via the increased ex-
pression of the norA gene [19,21,22]. This increased expres-
sion can be either constitutive, through the acquisition of 
mutations in the norA promoter region, or inducible, through 
the action of regulatory proteins [20,23,24]. The first muta-
tions to be described on norA promoter region were punctual 
mutations occurring 89 bp upstream of the initiation codon 
and downstream of the -10 motif, in the 5’-UTR region 
[19,21]. It has been suggested that these mutations may lead 
to an increase of the norA mRNA half-life, through an altera-
tion of the mRNA secondary structure, which could be less 
sensible to the action of RNases [25]. Other studies with 
strains carrying these punctual mutations have detected, in-
stead, an increase in norA transcripts resulting from an in-
creased rate of norA transcription [26]. More recently, sev-
eral groups have reported the occurrence of deletions and 
insertions in this same region, which may lead to increased 
norA mRNA stability [22,27,28]. To date, no correlation was 
found between antimicrobial resistance and mutations occur-
ring in norA coding region [13,15]. Besides alterations oc-
curring in norA promoter region, the production of NorA 
may also be regulated by several regulatory systems, albeit a 
clear regulatory pathway remains to be elucidated (see Part 
4). 
 Similarly to other efflux pumps belonging to the MFS, 
NorA uses the proton motive force to energize the transport 
of antimicrobial compounds across the cell membrane, via 
an H+:drug antiport mechanism. Studies have shown that the 
NorA-mediated efflux of ethidium bromide [18] and nor-
floxacin [19,21] is sensible to protonophores, such as car-
bonyl m-chlorophenylhydrazone (CCCP), which dissipates 
the membrane proton gradient. It was also demonstrated that 
the accumulation of norfloxacin in E. coli everted vesicles 
carrying a functional NorA was affected by the presence of 
nigericin, which also dissipates the membrane proton gradi-
ent, but not by valinomycin, which collapses the electric 
gradient, supporting the hypothesis that NorA-mediated ef-
flux is coupled to the proton gradient across the membrane 
[21].  
2.2. NorB 
 Since the first studies in NorA, evidence was gathered for 
the occurrence of other efflux systems in the chromosome of 
S. aureus [29,30]. The efflux pump NorB is structurally 
similar to the efflux pumps Blt (41%) and Bmr (30%) from 
B. subtilis, as well as to the S. aureus NorA (30%) and QacA 
(39%). It is a MFS proton-driven efflux pump composed by 
463 aminoacids, with 12 transmembrane segments. NorB 
confers resistance to some of the NorA substrates, such as 
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hydrophilic fluoroquinolones (norfloxacin and ciproflox-
acin), biocides (tetraphenylphosphonium and cetrimide) and 
the dye ethidium bromide, as well as to non-NorA substrates, 
such as the hydrophobic fluoroquinolones moxifloxacin and 
sparfloxacin, and to tetracycline [31]. A study with a mouse 
subcutaneous abscess model showed that NorB was impor-
tant for S. aureus fitness, suggesting a putative role for NorB 
in staphylococcal pathogenesis [32]. Following studies from 
the same group propose that NorB may be involved in S. 
aureus response to acid shock and reduced aeration, condi-
tions which triggered overexpression of norB gene [33,34]. 
In both cases, the overexpression of norB was associated 
with an increased resistance to NorB substrates, such as 
moxifloxacin [33,34]. In parallel with NorA, the regulation 
of NorB involves diverse regulatory pathways (see Part 4). 
2.3. NorC 
 The efflux pump NorC is codified by the chromosomal 
gene norC. It is a 462 aminoacid protein with 12 transmem-
brane segments that belongs to the MFS and shares 61% 
identity with NorB [35]. NorC is associated with low-level 
resistance towards hydrophilic and hydrophobic fluoroqui-
nolones, such as ciprofloxacin, moxifloxacin and garenox-
acin, and to the dye rhodamine [35,36]. Studies have indi-
cated that the wild-type expression of norC is apparently not 
sufficient to affect the susceptibility towards these com-
pounds, and that low-level resistance is achieved through 
norC overexpression [35].  
2.4. MepA 
 The efflux pump MepA was identified in studies with S. 
aureus norA disrupted mutants [37]. MepA is encoded by the 
chromosomal gene mepA and it was the first multidrug 
transporter from the MATE family to be described in S. 
aureus. This 451 aminoacid protein has 12 transmembrane 
segments and presents 26% and 21% identity to the MATE 
transporters CdeA from Clostridium difficile and NorM from 
Vibrio parahaemolyticus, respectively. MepA was found to 
be associated with a MDR phenotype, conferring low-level 
resistance to quaternary ammonium compounds, such as 
benzalkonium chloride, cetrimide, dequalinium, tetraphenyl-
phosphonium, pentamidine and the dye ethidium bromide, to 
chlorhexidine, pentamidine, as well as to tigecycline, an an-
tibiotic from the class of the glycylcyclines. The fluoroqui-
nolones ciprofloxacin and norfloxacin were shown to be 
weak substrates of MepA [37,38]. 
 The mepA gene is integrated in the mepRAB operon. Se-
quence analysis revealed that the encoded protein MepR is 
similar to regulatory proteins from the MarR family [37]. No 
significant similarity was found between MepB and any 
other protein with known function and no association was 
found between MepB and MDR phenotypes [37]. 
2.5. MdeA 
 The S. aureus chromosomal gene mdeA, which encodes 
the efflux pump MdeA, was identified in an open reading 
frame expression library of the S. aureus genome [39]. 
MdeA has 479 aminoacids, possesses 14 transmembrane 
segments and belongs to the MFS, using the proton motive 
force to energize the transport of its substrates. MdeA shares 
37% identity with the efflux pump LmrB from B. subtilis, 
24% with EmrB from E. coli and 23% with QacA from S. 
aureus [39]. The overexpression of mdeA was associated to 
increased resistance to the biocides benzalkonium chloride, 
dequalinium and tetraphenylphosphonium, to the dye 
ethidium bromide, and to the antibiotics virginiamycin, no-
vobiocin, mupirocin and fusidic acid [39]. A subsequent 
study showed that the fluoroquinolones norfloxacin and 
ciprofloxacin are weak substrates of this pump [40].  
 The overexpression of mdeA can be achieved by the oc-
currence of mutations in the mdeA promoter region, produc-
ing however only a slight increase in the MDR resistance 
phenotype [39]. 
2.6. Other Chromosomally-encoded MDR Efflux Pumps  
 The protein SepA, codified by the chromosomal gene 
sepA, has been identified as an efflux pump that confers low-
level resistance to antiseptic compounds, namely benzalk-
onium chloride, chlorhexidine gluconate and the dye acrifla-
vine [41]. This transporter comprises 157 aminoacids and 
four putative transmembrane segments, a characteristic of 
the transporters from the SMR family. However, the con-
served motifs of this family are not present in SepA, al-
though some residues important for the transport specificity 
and for the antiport H+:drug are present in a different loca-
tion, suggesting that SepA may belong to an yet identified 
family of transporters [41]. 
 SdrM is an efflux pump codified by the chromosomal 
gene sdrM. SdrM shares 23% and 21% identity with the S. 
aureus MDR efflux pumps NorB and QacA, respectively. 
Sequence analysis postulate that SdrM may belong to the 
MFS, possessing 14 transmembrane segments. This efflux 
pump was shown to be associated with low-level resistance 
to acriflavine, ethidium bromide and to the fluoroquinolone 
norfloxacin by promoting an energy-dependent efflux of 
these compounds [42].  
 More recently, Floyd and colleagues described another S. 
aureus multidrug efflux pump, LmrS (lincomycin resistance 
protein of S. aureus), with 39% identity with the lincomycin 
resistance protein LmrB of B. subtilis, and 25% identity with 
the efflux pumps FarB of Neisseria gonorrhoeae and EmrB 
of E. coli [43]. LmrS was described as a 480 aminoacid MFS 
protein, with 14 predicted membrane-spanning domains, 
being involved in increased resistance to linezolid and tetra-
phenylphosphonium chloride, sodium dodecyl sulfate, 
trimethoprim, and chloramphenicol [43]. 
3. PLASMID-ENCODED MDR EFFLUX PUMPS 
3.1. QacA/B 
 In the early 1980s, a gene encoding resistance to several 
antiseptics and disinfectants was identified on plasmid pSK1, 
carried by clinical isolates of S. aureus [44]. This gene, later 
designated qacA, encodes the efflux pump QacA that com-
prises 514 aminoacids and is a member of the MFS, presen-
ting 14 transmembrane segments [45]. The qacA gene is 
found in large conjugative plasmids not only from S. aureus 
strains, but also from coagulase-negative staphylococci [46]. 
QacA mediates resistance to a wide array of antimicrobial 
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compounds, more than 30 lipophilic, mono- and divalent 
cations, that belong to 12 distinct chemical classes, including 
dyes, such as ethidium bromide and rhodamine; quaternary 
ammonium compounds, like benzalkonium chloride, tetra-
phenylphosphonium and dequalinium; diamidines, such as 
pentamine and DAPI; biguanidines, like chlorhexidine; and 
guanylhydrazones [47-49]. The transport of these substrates 
is driven by the proton motive force via an antiport H+:drug 
mechanism [47,50].  
 Another antiseptic resistance determinant, the gene qacB, 
has been found in plasmids, isolated from strains of clinical 
origin dating from the 1950s [51]. The qacB gene encodes 
for the efflux pump QacB and was first described on plasmid 
pSK23 [52]. qacB is closely related to the qacA gene, differ-
ing in only seven nucleotides in the entire sequence. Even so, 
the substrate specificity of both pumps varies, with QacB 
conferring resistance to only monovalent lipophilic cations 
[52,53]. Mutagenesis analysis revealed that the presence of 
aspartic acid at the position 323 of QacA, located within the 
transmembrane segment 10, instead of an alanine in QacB, is 
critical for conveying resistance to divalent cations. More-
over, it indicates that an acidic charge in that position is es-
sential for the binding of divalent substrates and that QacA 
has two different binding sites for substrates [53,54], which 
was also confirmed by kinetic analysis of the QacA transport 
of monovalent and divalent fluorescent substrates [50]. 
 Analysis of the qacA/B genes carried by S. aureus clini-
cal isolates has revealed the occurrence of some genetic vari-
ability of these genes and that these variant forms of either 
QacA or QacB may confer different levels of resistance to 
biocides and dyes [55]. In addition, a recent study indicated 
that a clinical isolate harboring a variant of QacB, that car-
ried a glutamic acid instead of alanine in position 320, which 
is located in the transmembrane segment 10, conferred low-
level resistance to the hydrophilic fluoroquinolones norflox-
acin and ciprofloxacin [56]. 
3.2. Smr 
 The efflux pump gene smr was identified in the late 
1980s by different groups in several plasmids conferring 
antiseptic and ethidium bromide resistance. This gene was 
designated ebr [57], qacC/D [58] or smr [59], but sequence 
analysis of the determinants described by these authors re-
vealed that they were all identical. This gene can be found in 
either small non-conjugative plasmids, such as pSK89, or 
large conjugative plasmids, like pSK41, in both S. aureus 
and coagulase-negative staphylocci, and encodes the efflux 
pump Smr [46,58,60].  
 Hydropathy analysis revealed that Smr, with 107 amino-
acids, has four transmembrane segments and belongs to the 
SMR family that uses the proton motive force to energize the 
transport of noxious compounds [61]. This efflux pump con-
veys low-level resistance to a narrower number of com-
pounds when compared with QacA/B, namely monovalent 
cationic dyes, such as ethidium bromide, and quaternary 
ammonium compounds, such as benzalkonium chloride [61]. 
 Due to its small size, it was questioned if Smr, as a 
monomer, would be able to conduct the transport of the sub-
strates. In vitro transport assays with purified Smr and site-
directed mutagenesis, showed that it is capable of perform-
ing efflux, without however clarifying if as a monomer or as 
an oligomer [61,62], as described for other pumps of the 
SMR family [63].  
 Sequence analysis of the smr gene found in several plas-
mids showed that it is highly conserved, with only one vari-
ant, smr’, which shows a single nucleotide alteration that 
results in the change of an alanine by a serine at residue 9, 
producing the Smr’ protein. It was demonstrated that Smr’ 
conveyed a resistance phenotype similar to Smr [64]. How-
ever, the regions flanking smr showed some diversity, lead-
ing to the classification of smr cassette-like structures (com-
prising the smr gene flanked by direct repeats) in three dis-
tinct groups (types 1 to 3), apparently with no differences at 
the type or level of resistance conferred [60,65,66].  
3.3. Other Plasmid-encoded MDR Efflux Pumps 
 Other S. aureus plasmid-borne efflux pumps conferring 
resistance to antiseptics and disinfectants include QacG, 
QacH and QacJ. 
 The efflux pump gene qacG was identified in S. aureus 
isolates collected in the food industry. This gene was located 
on the 2.3 kb plasmid pST94. It encodes the efflux pump 
QacG that has 107 aminoacids and four transmembrane 
segments, shares 69.2% identity with the efflux pump Smr 
and belongs to the SMR family of transporters [67]. The 
determinant qacH was first detected in a 2.4 kb plasmid iso-
lated from a Staphylococcus saprophyticus strain from the 
food industry. The qacH gene shares 76% and 70% nucleo-
tide identity to the smr and qacG genes, respectively, and 
encodes the efflux pump QacH, with 107 aminoacid residues 
and four transmembrane segments, that belongs to the SMR 
family [68]. The efflux pump gene qacJ was identified on a 
2.65 kb plasmid found in several strains from three staphylo-
coccal species; S. aureus, Staphylococcus simulans and 
Staphylococcus intermedius, all collected from horses [69]. 
The encoded efflux pump QacJ also belongs to the SMR 
family, with 107 aminoacids and four transmembrane seg-
ments, and shares 72.5%, 82.6% and 73.4% identity with the 
efflux pumps Smr, QacG and QacH, respectively. 
 Despite the differences found between the aminoacid 
sequences of Smr and QacG/H/J, all these pumps share al-
most identical substrate specificities, conferring similar lev-
els of resistance to benzalkonium chloride, ethidium bromide 
and cetyltrymethylammonium bromide [69]. 
4. REGULATION OF S. aureus MDR EFFLUX PUMPS 
4.1. Global Regulators 
 The regulation of S. aureus MDR efflux pump genes is 
complex and is affected by several global regulators that act 
in an intricate regulatory network and are involved in chemi-
cal and physical stress response as well as in S. aureus 
pathogenesis. 
 The regulator MgrA, previously named NorR or Rat, was 
first identified by its binding to the norA promoter region 
[70]. MgrA is highly homologous to MarR family proteins 
and in a lesser-extent to SarA family proteins, both transcrip-
tional regulatory proteins that possess a helix-turn-helix mo-
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tif involved in the specific binding to DNA [71,72]. MgrA is 
a pleiotropic regulator that uses an oxidation-sensing mecha-
nism [73] in the regulation of autolysis, virulence genes, 
antibiotic resistance genes (efflux pumps) and other genes 
involved in the S. aureus metabolism [74,75]. This regulator 
was also found to modulate the expression of other global 
regulators, such as SarA, which affects the expression of 
virulence determinants [76] and the alternative sigma factor 
SigB, essential for the S. aureus chemical and stress re-
sponse [77,78]. These findings suggest that some modulation 
effects attributed to MgrA may be achieved in an indirect 
manner [75].  
 MgrA regulates three S. aureus MDR efflux pumps; 
NorA, NorB and NorC, as well as the non-MDR tetracycline 
efflux pump Tet38 and the ABC efflux pump AbcA 
[31,79,80]. Reports from different groups studying MgrA 
had reported divergent effects of this regulator on the norA 
and norB expression in genetic backgrounds that differed in 
the rsbU locus, that encodes the protein RsbU from the ser-
ine/threonine phosphatase family [26,31,70,75,79]. A thor-
ough examination of these genetic systems evidenced that 
MgrA can be post-translationally phosphorylated by the pu-
tative serine/threonine kinase PknB [81], and that the phos-
phorylated MgrA-P can be dephosphorylated by RsbU [82], 
altering the ability of MgrA to bind to the norA/B promoters. 
A model for MgrA norA/B modulation was proposed after 
the demonstration that only MgrA was able to bind to the 
norA promoter and only MgrA-P could bind to norB pro-
moter. According to this model, MgrA acts as a norA repres-
sor, and upon phosphorylation, MgrA-P is released from the 
norA promoter, allowing norA transcription. The MgrA-P 
will, in turn, bind to the norB promoter, acting as a repressor 
of norB [82]. The cellular ratio between MgrA and MgrA-P 
(and hence their effect on efflux pump expression) is de-
pendent of PknB and RsbU, which in turn are modulated by 
the alternative sigma factor SigB, involved in S. aureus 
stress response. 
 It was proposed that NorC may be negatively regulated 
by MgrA, acting in a concerted manner with NorB. How-
ever, no MgrA recognition sites were found in the norC 
promoter region, suggesting that MgrA may have an indirect 
effect over norC expression and that other factors may play a 
role in the production of this efflux pump [35]. 
 The transcriptional regulator NorG, from the GntR-like 
family, was identified by binding to the norA promoter in a 
mgrA- background [80]. It was shown that NorG was able to 
bind specifically to the promoters of the efflux pump genes 
norA, norB, norC, abcA as well as to its own promoter. No 
binding of NorG to the tet38 or mgrA promoters was de-
tected [80]. However, MgrA may bind to the norG promoter, 
thus affecting its expression [80]. Despite the binding of 
NorG to the promoter regions of norA, norB, norC and abcA, 
overexpression of norG was accompanied only by a mild 
increase in norB expression, suggesting that NorG is an acti-
vator of norB [80]. An analysis of the transcriptional profile 
of NorG confirmed its role as an activator of NorB and re-
vealed that NorG affects negatively the expression of both 
norC and abcA [36]. It also showed that NorG activates the 
transcription of the global regulators mgrA, arlS and sarZ. 
SarZ, a MgrA homologue involved in the oxidative stress 
response of S. aureus was previously shown to downregulate 
norB and tet38 expression [83]. It has been documented that 
NorG is absent from some prototype S. aureus strains, such 
as MW2, MSSA476 and MRSA 252, showing that NorG 
may not be essential for efflux pump regulation in these 
strains [84]. 
 The expression of the NorA and NorB can be also modu-
lated by the two-component regulatory system ArlRS, in-
volved in adhesion, autolysis and extracellular proteolytic 
activity of S. aureus [70,85,86]. 
 A recent study revealed that norA expression can be addi-
tionally modulated by fur, a ferric uptake regulator that has a 
putative binding site in the norA promoter region. It also 
showed that NorA is iron responsive and may contribute to 
the export of siderophores in S. aureus [87]. 
4.2. Specific Regulators 
 In addition to global regulators described above, the tran-
scription of the genes coding for some S. aureus MDR efflux 
pumps can also be modulated by specific regulators. This is 
the case for MepA and QacA/B, regulated by MepR and 
QacR, respectively. Both these regulators function as sen-
sors, binding to the substrates of the MDR efflux pumps and 
inducing their expression, thus acting as substrate-responsive 
regulators. 
 MepR is a self-repressive protein that binds to sequences 
in which pseudo palindromes are present, as well as to the 
motif GTTAG, both located in the promoter regions of mepR 
and mepA. MepR does not bind to the mepB promoter region 
[88]. The binding of MepR is stronger with the mepA pro-
moter than with the mepR promoter, and the stoichiometry of 
this binding is probably different [89]. The mepA promoter 
presents both high- and low-affinity MepR binding sites that 
overlap with the -35 and -10 consensus sequences, resulting 
in a tight repression of mepA by MepR, which may bind as 
two dimers. On the other hand, the weaker and smaller 
MepR binding site in mepR promoter encompasses the tran-
scription initiation site, located immediately downstream of 
the -10 consensus sequence, which can result in a weaker 
interaction with MepR that is thought to bind as a single 
dimer [89]. The weaker repression of mepR could explain the 
observation that only mepR transcripts are detected in wild-
type strains [37,88]. Analysis of mutant strains overexpress-
ing the mepA gene were found to have mutations in MepR, 
such as the introduction of premature stop codons and con-
sequently the production of truncated forms of MepR that 
can render the protein non-functional, thus enabling the tran-
scription of the mepA gene [37,89]. 
 The auto-regulatory MepR is also responsive to the pres-
ence of MepA substrates, although the substrate specificity 
of MepA and MepR do not entirely overlap [88,90]. There is 
evidence that MepR binds to several MepA substrates, and it 
is postulated that the binding of the MepR substrate induces 
a change in MepR conformation so that the interaction be-
tween MepR and the DNA binding sites is diminished 
[89,90]. 
 QacR is encoded by the gene qacR that occurs immedi-
ately upstream of the genes qacA and qacB being transcribed 
divergently to these genes [45]. QacR possesses a helix-turn-
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helix DNA binding motif, common to regulatory proteins, 
and belongs to the TetR family of transcriptional repressors 
[45]. It has been shown that QacR is a direct repressor of the 
expression of the qacA gene, by binding to the qacA pro-
moter [91]. QacR binds to a large inverted repeat (IR1) that 
is located immediately downstream of the qacA/B promoters 
and overlaps the qacA/B transcription initiation sites [92]. 
The binding mechanism of QacR to IR1 differs from that of 
other TetR family of regulatory proteins, with two dimers of 
QacR binding cooperatively to IR1, not through protein-
protein interactions but via a widened conformation of the 
DNA promoted by the binding of the first QacR dimer that 
favors the binding of the second one [93]. When bound to 
the IR1 in the qacA promoter, QacR represses the transcrip-
tion of this gene [91]. However, upon addition of QacA sub-
strates, qacA expression increases in a substrate concentra-
tion-dependent manner by inhibition of the QacR binding to 
the qacA promoter [91]. This inhibition is achieved by the 
direct interaction of QacR to the wide array of QacA sub-
strates [91]. Thus, QacR is also a multidrug-binding protein, 
for which several structures of complexes QacR:drug have 
been determined and have revealed the presence of several, 
distinct, but linked binding sites within one extended and 
multifaceted binding pocket that has evolved to accommo-
date the broadest range of noxious hydrophobic molecules 
[94,95]. The binding of a QacA substrate to QacR results in 
a change in QacR conformation, which renders the protein 
unable to bind IR1, thus allowing qacA transcription [94]. 
Not all compounds that are QacA substrates were shown to 
induce qacA expression or to inhibit the QacR binding to 
IR1, suggesting that there is a basal qacA expression and 
thus QacR is a relatively weak repressor [91]. 
 The increased activity or synthesis of the efflux pumps 
described above, which can occur in response to several 
chemical or environmental stimuli, potentiates the survival 
of antimicrobial resistant S. aureus, which may have relevant 
implications in the management of these infections in the 
clinical settings.  
5. CLINICAL SIGNIFICANCE OF MDR EFFLUX 
PUMPS IN S. aureus 
 In bacteria, clinically significant resistance mediated by 
drug efflux can encompass either antibiotics, biocides, or 
both. Efflux-mediated antibiotic resistance may involve ef-
flux systems capable of extruding a single class of antibiot-
ics, such as the case of the Tet determinants that convey re-
sistance to tetracycline, or the extrusion of multiple classes 
of antibiotics by MDR efflux pumps, such as the ones de-
scribed in this review. The overexpression of MDR efflux 
pumps, due to their promiscuous substrate specificity, can 
promote resistance to several classes of antibiotics but also 
decreased susceptibility to biocides, resulting into a mul-
tidrug resistance phenotype [7]. Besides the risk of therapeu-
tic failure, the development of these multidrug resistance 
phenotypes may give rise to other problems, such as the pos-
sible co-selection and cross-resistance between efflux medi-
ated antibiotic and biocide resistance, particularly worrisome 
for drug resistant strains such as MRSA strains. 
5.1. Assessing Efflux Activity 
 To fully ascertain the role played by a given efflux sys-
tem in antibiotic and/or biocide resistance, one must assure 
that the methodology applied is the most adequate to dis-
close efflux activity. The majority of the studies on efflux-
mediated resistance among S. aureus clinical isolates use the 
decrease of antibiotic minimum inhibitory concentration 
(MIC) in the presence of compounds described to inhibit 
efflux activity, the so called efflux inhibitors (EIs) [27,96-
101]. This approach is laborious and dependent on the sus-
ceptibility of the efflux system(s) to that particular inhibitor, 
which can vary considerably and for which the mechanism 
of action at the cellular level remains, in most cases, to be 
clarified [101-103].  
 More recently, ethidium bromide, a broad range efflux 
pump substrate, has been explored to assess efflux activity in 
S. aureus cells. This molecule can be used as a marker for 
the indirect assessment of efflux activity, namely, by deter-
mination of ethidium bromide MICs to identify S. aureus 
strains that show increased efflux activity [84,104] in the 
presence/absence of efflux inhibitors [22,105], by the 
Ethidium Bromide-Agar Cartwheel Method, which evaluates 
the cells capacity to retain/extrude ethidium bromide after 
overnight incubation [106] or in assays that evaluate directly 
the efflux activity, using real-time fluorometry [107]. 
5.2. Efflux-mediated Fluoroquinolone Resistance 
 Reports of antibiotic resistance mediated by efflux pumps 
in S. aureus include many classes of antibiotics, with par-
ticular emphasis for tetracyclines, macrolides and fluoroqui-
nolones. Nevertheless, is on fluoroquinolones that much at-
tention has been focused since this class of antibiotics in-
cludes many substrates of a large number of MDR efflux 
systems [108]. Fluoroquinolone resistance in S. aureus has 
been mainly attributed to mutations occurring in the cellular 
targets GrlA/GrlB (topoisomerase IV, encoded by genes 
grlA/grlB) and GyrA/GyrB (DNA gyrase, encoded by genes 
gyrA/ gyrB); which decrease their affinity to the drug, con-
ferring high-level fluoroquinolone resistance [109-111]. Ef-
flux-mediated resistance to fluoroquinolones, such as cipro-
floxacin, norfloxacin and sparfloxacin, has been described in 
S. aureus clinical isolates for the last two decades, albeit 
sporadically [96-98,112-116]. However, the role played by 
each individual efflux system is difficult to establish, since 
the majority of the chromosomal MDR efflux pumps extrude 
fluoroquinolones. All these factors contribute for the rela-
tively poor characterization of efflux-mediated fluoroqui-
nolone resistance in clinical S. aureus isolates [117].  
 Very few reports relate the actual contribution of each 
chromosomal MDR efflux pump to the resistance of S. 
aureus towards fluoroquinolones. A study by DeMarco et al. 
reported the occurrence of 49% of strains showing increased 
efflux activity within a collection of 232 bloodstream S. 
aureus isolates [27]. The increased efflux activity present in 
those isolates was correlated with increased resistance to 
fluoroquinolones, biocides and dyes. Efflux pump gene ex-
pression assays revealed that among strains with increased 
efflux activity, nearly half (48%) overexpressed MDR efflux 
pumps. Of these last ones, 57% strains showed overexpres-
sion of a single efflux pump gene, most commonly norA or 
mepA, while the remaining 43% isolates overexpressed two 
or more efflux pump genes, predominantly norB/C [27]. A 
recent study from our group on a collection of 52 ciproflox-
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acin resistant isolates detected increased efflux activity in 
23% of the isolates, which was associated with increased 
resistance to fluoroquinolones [105]. These isolates with 
increased efflux activity showed a strong involvement of 
efflux in the resistance phenotype, but assessment of gene 
expression in representative isolates revealed low levels of 
efflux pump gene expression, which occurred only in the 
presence of agents, such as ciprofloxacin. The opposite ef-
fect was observed for a pan-susceptible reference strain, sug-
gesting that the clinical isolates could be already primed to 
respond to noxious compounds. In fact, these isolates are 
under a constant pressure by antimicrobial compounds, such 
as antibiotics and biocides. Since the expression of efflux 
pumps provides the cell with the means to cope with these 
compounds, it could be expected that those clinical isolates 
already have in their cell membrane the necessary number of 
efflux pump proteins [105]. We also observed that not only 
different substrates can trigger expression of different efflux 
pump genes for the same strain, but also that the same sub-
strate can promote a variable response, according to its con-
centration. The pattern of gene expression encountered in 
this study showed some differences from the one found by 
DeMarco et al., the most striking being the absence of norA 
overexpression [105]. A different MDR pumps expression 
pattern was also reported for S. aureus prototype strains [84]. 
Altogether, these studies reveal that S. aureus clinical iso-
lates may diverge in the efflux-mediated response to noxious 
agents, including fluoroquinolones, even when highly 
clonally related [105]. 
5.3. Efflux-mediated Biocide Resistance 
 Biocides play an important role in infection control and 
hygiene, being extensively used in health care settings, con-
sumer products, animal husbandry and food industry [118]. 
Resistance to biocides has been reported since the 1950s 
[119], with particular focus on bacterial resistance towards 
quaternary ammonium compounds used as disinfectants 
[120-122]. The action of biocides differs from the one of 
antibiotics by the multiplicity of their targets within the bac-
terial cell. Thus, emergence of resistance towards these com-
pounds rarely occurs by mechanisms such as the modifica-
tion of target sites. Instead, resistance to biocides is more 
often associated with the reduction of the biocide intracellu-
lar concentration, either by a decrease in cell wall permeabil-
ity or efflux of the biocide [118]. In S. aureus, resistance to 
antiseptics and disinfectants has been mainly attributed to the 
plasmid-encoded efflux systems, QacA/B, Smr, QacG, QacH 
and QacJ. The few reports on the prevalence of these genes 
suggest that their distribution may follow a geographic varia-
tion, albeit more and larger studies are necessary to draw a 
more accurate portrait of this distribution. Studies with clini-
cal isolates conducted in Asian countries have reported 
prevalences from 0% to 73% for qacA/B genes and 0 to 32% 
for the smr gene [123,124], although several reports from 
Japan spanning several years apart have reported a constant 
prevalence of around 35% and 3% for genes qacA/B and 
smr, respectively [55,125,126]. Reports from Europe have 
also described different prevalence values; Mayer et al. de-
scribed a prevalence of 42% of qacA/B and 6% of smr genes  
 
among a collection of 497 clinical isolates [127], while oth-
ers have reported values of 8.3% and 44% [128], and 15% 
and 4%, respectively [129]. In our own study of a collection 
of 53 S. aureus clinical isolates from a Portuguese hospital, 
we found 1.9% occurrence of qacA and smr genes [105, un-
published data]. A recent study with S. aureus clinical iso-
lates from Tunisia reported the occurrence of 13% isolates 
carrying qacA, 9% carrying qacB and 11% with smr genes 
[130]. Another recent report from Canada revealed the oc-
currence of the qacA/B and smr genes in 2% and 7%, respec-
tively, amongst a collection of 344 S. aureus clinical isolates 
[131]. The majority of these studies describe the co-
occurrence of both qacA/B and smr genes in the same isolate 
[55,123,127-130]. 
 The occurrence of other qac genes, namely qacG, qacH 
and qacJ, has been mainly described in isolates of animal 
origin and food industry [65,132]. However, a study reported 
the carriage of qacH gene by 3% of 120 MRSA isolates from 
the United Kingdom [128], and another recent study re-
vealed the presence of these genes in S. aureus clinical iso-
lates, but with very low-prevalence rates, 0.5% for qacH, 
2.2% for qacG and 1.3% for qacJ [133]. This last study also 
referred the joint co-occurrence of qacG and qacA/B or smr 
[133]. 
 The occurrence of the qacA/B gene is mainly associated 
with high-level resistance to several antiseptics, disinfectants 
and dyes. We have previously demonstrated the carriage of 
the qacA gene in a ca. 30-kb plasmid by the MRSA strain 
HPV107, representative of the so-called MRSA Iberian 
clone that is disseminated throughout several European 
countries and the USA [134]. By curing HPV107 of this 
plasmid and comparing the initial and the plasmid-cured 
culture, we could establish an association between carriage 
of this plasmid/QacA determinant and a higher efflux activ-
ity in strain HPV107, showing also that this activity was 
linked to the reduced susceptibility towards several biocide 
compounds showed by HPV107. In particular, the plasmid-
cured derivative of HPV107 became more susceptible to all 
biocides tested, which included tetraphenylphosphonium 
bromide, dequalinium chloride, benzalkonium chloride, 
hexadecyltrimethylammonium bromide, cetrimide, and pen-
tamidine, with exception of chlorhexidine, for which no al-
teration was detected, and to the dyes ethidium bromide, 
berberine, acriflavine and crystal violet. On the other hand, 
no alterations were detected in the antibiotic-resistant profile 
of the plasmid-cured strain [134].  
 Chromosomally encoded MDR efflux pumps are also 
capable of conferring resistance to biocides. In S. aureus, all 
MDR efflux pumps encoded in the chromosome have the 
potential to extrude biocides and are associated with low- to 
high-level resistance to these compounds. However, the as-
sessment of their involvement in biocide resistance is more 
difficult to ascertain, since these efllux pumps occur natu-
rally in S. aureus. Several studies have associated a biocide 
resistance phenotype in clinical isolates with the overexpres-
sion of efflux pump genes. Huet et al. demonstrated that the 
selective pressure of biocides could result in increased resis-
tance to these compounds due to the overexpression of efflux 
pumps such as mepA, norA, norC and mdeA [28].  
MDR Efflux Pumps in Staphylococcus aureus The Open Microbiology Journal, 2013, Volume 7    67 
5.4. The role of Efflux on the Relation between Antibiotic 
and Biocide Resistance 
 The question of whether biocide resistance can have a 
role on the selection of antibiotic-resistant strains has been a 
matter of debate [118,120,135,136]. Data available on litera-
ture report contradictory data concerning the relation be-
tween antibiotic and biocide resistance, but evidence has 
been gathered supporting the occurrence of co-selection of 
strains with reduced susceptibility to biocides by antibiotic-
resistant bacteria, and vice-versa [137-141].  
 In S. aureus, many MDR efflux pumps involved in bio-
cide resistance are encoded on large conjugative plasmids 
that can also carry other resistance determinants [52]. One 
such example is the linkage between qacA and the gene 
blaZ, which encodes a -lactamase. Several reports have 
described an association between biocide resistance and 
penicillin resistant staphylococci isolates of animal [142] and 
human origin [143], due to the dissemination of multiresis-
tance plasmids carrying both qacA/B and blaZ. The qacA 
gene can also be encountered in plasmids together with 
genes encoding resistance to trimethoprim, aminoglycosides, 
fosfomycin and heavy-metals [144-146]. 
 Another point of debate is the co-selection of MRSA 
strains by strains harbouring qac genes. Although some stud-
ies have found no linkage between MRSA and qacA/B car-
riage [147], others studies suggest the opposite [55, 127]. A 
recent study by Zhang et al. has showed that qac genes were 
more frequent in MRSA strains that colonized nurses than 
the general public [148]. 
 The role played by efflux pumps on the development of 
resistance to several types of antimicrobial agents has been 
demonstrated by the step-wise adaptation of a susceptible 
strain to ethidium bromide, which resulted in an adapted 
strain with increased resistance not only to ethidium bromide 
but to several other antimicrobial compounds, including 
fluoroquinolones. This multidrug resistance phenotype was 
due to the overexpression of a single MDR efflux pump, 
NorA [22]. Huet et al. have also shown that single- and 
multi-step exposure of S. aureus strains to different biocides 
and dyes resulted in MDR phenotypes, by overexpression of 
efflux pump genes [28]. 
6. CONCLUSIONS 
 For a long time, the role of efflux pumps in antibiotic 
resistance was neglected, in particular for Gram-positive 
bacteria. The last decade witnessed a significant build-up of 
information on these systems, in particular on MDR efflux 
pumps. Nevertheless, our current understanding on how 
these systems operate and respond to the environmental 
pressure created by antimicrobial agents is still relatively 
dispersed.  
 Several aspects have prevented the understanding of a 
clear picture of the real role efflux pumps play in the appear-
ance of bacterial resistance to antimicrobial compounds.  
 
First, the fact that the level of resistance attributable to ef-
flux-mediated resistance is, in most of the cases, lower than 
the one conferred by the other resistance mechanisms and 
sometimes difficult to establish, depending on the method 
used to evaluate efflux activity. Second, bacterial response to 
these compounds is mediated, in most of the cases, not by a 
single but by several efflux pumps, that react in a concerted 
manner to the presence of the antimicrobial, which difficults 
the perception of the role played by each individual pump on 
the overall efflux activity/resistance phenotype. Third, bacte-
rial efflux systems are regulated by several specific and/or 
global regulators that act in an intricate network of regula-
tory/sensory pathways, which may confuse our interpretation 
of data. Finally, there is still a lack of consensual methodo-
logical approaches that guarantee appropriate address of all 
these issues. 
 The pertinence of these questions becomes more obvious 
when studying efflux activity in collections of clinical 
strains, for which the myriad of responses difficult even 
more a clear interpretation of data. The few studies of efflux-
mediated antimicrobial resistance on S. aureus of clinical 
origin revealed that more than a specific efflux-mediated 
response to a specific stimuli (antimicrobial agent), one may 
observe distinct responses to the same stimuli. This probably 
results from the specific effect of that stimulus on each spe-
cific strain, as the result of the strain genetic background and 
responsive efflux systems.  
 It is established that efflux pumps contribute to low level 
resistance to antimicrobial agents and the emergence of 
MDR phenotypes in clinical strains by the extrusion of mul-
tiple, unrelated compounds, including antibiotics and bio-
cides. The interrelations between these two groups of anti-
microbials in the inducement of resistance is not yet clarified 
but the promiscuous activity of MDR efflux pumps foresee a 
close relation in the development of efflux-mediated resis-
tance to both types of antimicrobials. 
 Recent studies from independent groups, working with 
different bacteria, suggest that efflux systems may be a first 
response to the antimicrobial making possible for the cell to 
survive and acquire other, more stable resistance mecha-
nisms that will then provide a high-level resistance pheno-
type, as was recently demonstrated for E. coli [149] and My-
cobacterium tuberculosis [150]. In S. aureus, some evi-
dences have been also found for this role of efflux pumps as 
a first-line defense mechanism towards noxious compounds 
[151,152] that are supported by data on clinical strains 
[27,28,105]. 
 All these observations open new perspectives for the fu-
ture work on efflux pumps, which may include a new thera-
peutic concept on the usefulness of efflux inhibitors as adju-
vants of the conventional anti-bacterial therapy to overcome 
the scarcity of therapeutic approaches for these MDR infec-
tions [100].  
CONFLICT OF INTEREST 
 The authors confirm that this article content has no con-
flicts of interest.  
ACKNOWLEDGEMENTS 
 This study was supported by Fundação para a Ciência e a 
Tecnologia (FCT, Portugal), through grants PEst-
OE/BIA/UI0457/2011 and PTDC/BIA-MIC/105509/2008. 
68    The Open Microbiology Journal, 2013, Volume 7 Costa et al. 
 S. S. Costa is the recipient of doctoral grant 
SFRH/BD/44214/2008, from Fundação para a Ciência e a 
Tecnologia (FCT, Portugal).  
 We would like to acknowledge all our colleagues that 
have directly or indirectly, contributed to our studies on bac-
terial efflux systems. 
REFERENCES 
[1] Davies J, Davies D. Origins and evolution of antibiotic resistance. 
Microbiol Mol Biol Rev 2010; 74: 417-33.  
[2] Rice LB. The clinical consequences of antimicrobial resistance. 
Curr Opin Microbiol 2009; 12: 1-6. 
[3] Livermore DM. Has the era of untreatable infections arrived? J 
Antimicrob Chemother 2009; 64(S1): i29-36. 
[4] Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 
339: 520-32. 
[5] Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus 
aureus in the antibiotic era. Nat Rev Microbiol 2009; 7: 629-41. 
[6] David MZ, Daum RS. Community-associated methicillin-resistant 
Staphylococcus aureus: epidemiology and clinical consequences of 
an emerging epidemic. Clin Microbiol Rev 2010; 23: 616–87.  
[7] Piddock LJV. Clinically relevant chromosomally encoded mul-
tidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 
2006; 19: 382-402. 
[8] Alekshun MN, Levy SB. Molecular mechanisms of antibacterial 
multidrug resistance. Cell 2007; 128: 1037-50. 
[9] Piddock LJV. Multidrug-resistance efflux pumps - not just for 
resistance. Nat Rev Microbiol 2006; 4: 629-36. 
[10] Poole K. Bacterial multidrug efflux pumps serve other functions. 
Microbe 2008; 3: 179-85. 
[11] Kumar A, Schweizer HP. Bacterial resistance to antibiotics: active 
efflux and reduced uptake. Adv Drug Deliv Rev 2005; 57: 1486-
513. 
[12] Ubukata K, Itoh-Yamashita N, Konno M. Cloning and expression 
of the norA gene for fluoroquinolone resistance in Staphylococcus 
aureus. Antimicrob Agents Chemother 1989; 33: 1535-9. 
[13] Schmitz FJ, Hertel B, Hofmann B, et al. Relationship between 
mutations in the coding and promoter regions and the norA genes 
in 42 unrelated clinical isolates of Staphylococcus aureus and the 
MICs of norfloxacin for these strains. J Antimicrob Chemother 
1998; 42: 561-3. 
[14] Sierra JM, Ruiz J, de Anta MTJ, et al. Prevalence of two different 
genes encoding NorA in 23 clinical strains of Staphylococcus 
aureus. J Antimicrob Chemother 2000; 46: 145-6. 
[15] Noguchi N, Okada H, Narui K, et al. Comparison of the nucleotide 
sequence and expression of norA genes and microbial susceptibility 
in 21 strains of Staphylococcus aureus. Microb Drug Resist 2004; 
10: 197-203. 
[16] Yoshida, H, Bogaki M, Nakamura S, et al. Nucleotide sequence 
and characterization of the Staphylococcus aureus norA gene, 
which confers resistance to quinolones. J Bacteriol 1990; 172: 
6942-9. 
[17] Neyfakh AA. The multidrug efflux transporter of Bacillus subtilis 
is a structural and functional homolog of the Staphylococcus 
aureus NorA protein. Antimicrob Agents Chemother 1992; 36: 
484-5. 
[18] Neyfakh AA, Borsch CM, Kaatz GW. Fluoroquinolone resistance 
protein NorA of Staphylococcus aureus is a multidrug efflux trans-
porter. Antimicrob Agents Chemother 1993; 37: 128-9. 
[19] Kaatz GW, Seo SM, Ruble CA. Efflux-mediated fluoroquinolone 
resistance in Staphylococcus aureus. Antimicrob Agents Chemo-
ther 1993; 37: 1086-94. 
[20] Kaatz GW, Seo SM. Inducible NorA-mediated multidrug resistance 
in Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 
2650-5. 
[21] Ng EYW, Trucksis M, Hooper DC. Quinolone resistance mediated 
by norA: physiologic characterization and relationship to flqB, a 
quinolone resistance locus on the Staphylococcus aureus chromo-
some. Antimicrob Agents Chemother 1994; 38: 1345-55. 
[22] Couto I, Costa SS, Viveiros M, et al. Efflux-mediated response of 
Staphylococcus aureus exposed to ethidium bromide. J Antimicrob 
Chemother 2008; 62: 504-13. 
[23] Kaatz GW, Seo SM. Mechanisms of fluoroquinolone resistance in 
genetically related strains of Staphylococcus aureus. Antimicrob 
Agents Chemother 1997; 41: 2733-7. 
[24] Kaatz GW, Seo SM. Effect of substrate exposure and other growth 
condition manipulations on norA expression. J Antimicrob Chemo-
ther 2004; 54: 364-9. 
[25] Fournier B, Truong-Bolduc QC, Zhang X, et al. A mutation in the 
5’ untranslated region increases stability of norA mRNA, encoding 
a multidrug resistance transporter of Staphylococcus aureus. J Bac-
teriol 2001; 183: 2367-71. 
[26] Kaatz GW, Thyagarajan RV, Seo SM. Effect of promoter region 
mutations and mgrA overexpression on transcription of norA, 
which encodes a Staphylococcus aureus multidrug efflux trans-
porter. Antimicrob Agents Chemother 2005; 49:161-9. 
[27] DeMarco CE, Cushing LA, Frempong-Manso E, et al. Efflux-
related resistance to norfloxacin, dyes, and biocides in bloodstream 
isolates of Staphylococcus aureus. Antimicrob Agents Chemother 
2007; 51: 3235-9. 
[28] Huet AA, Raygada JL, Mendiratta K, et al. Multidrug efflux pump 
overexpression in Staphylococcus aureus after single and multiple 
in vitro exposures to biocides and dyes. Microbiol 2008; 154: 
3144-53. 
[29] Kaatz GW, Seo SM, O’Brien L, et al. Evidence for the existence of 
a multidrug efflux pump transporter distinct from NorA in Staphy-
lococcus aureus. Antimicrob Agents Chemother 2000; 44: 1404-6. 
[30] Kaatz GW, Moudgal VV, Seo SM. Identification and characteriza-
tion of a novel efflux-related multidrug resistance phenotype in 
Staphylococcus aureus. J Antimicrob Chemother 2002; 50: 833-8. 
[31] Truong-Bolduc QC, Dunman PM, Strahilevitz J, et al. MgrA is a 
multiple regulator of two new efflux pumps in Staphylococcus 
aureus. J Bacteriol 2005; 187: 2395-405. 
[32] Ding Y, Onodera Y, Lee JC, et al. NorB, an efflux pump in Staphy-
lococcus aureus strain MW2, contributes to bacterial fitness in ab-
scesses. J Bacteriol 2008; 190: 7123-9. 
[33] Truong-Bolduc QC, Bolduc GR, Okumura R, et al. Implication of 
the NorB efflux pump in the adaptation of Staphylococcus aureus 
to growth at acid pH and in resistance to moxifloxacin. Antimicrob 
Agents Chemother 2011; 55: 3214-9. 
[34] Truong-Bolduc QC, Hsing LC, Villet R, et al. Reduced aeration 
affects the expression of the NorB efflux pump of Staphylococcus 
aureus by posttranslational modification of MgrA. J Bacteriol 
2012; 194: 1823-34. 
[35] Truong-Bolduc QC, Strahilevitz J, Hooper DC. NorC, a new efflux 
pump regulated by MgrA of Staphylococcus aureus. Antimicrob 
Agents Chemother 2006; 50: 1104-7. 
[36] Truong-Bolduc QC, Dunman PM, Eidem T, et al. Transcriptional 
profiling analysis of the global regulator NorG, a GntR-like protein 
of Staphylococcus aureus. J Bacteriol 2011; 193: 6207-14. 
[37] Kaatz GW, McAleese F, Seo SM. Multidrug resistance in Staphy-
lococcus aureus due to overexpression of a novel multidrug and 
toxin extrusion (MATE) transport protein. Antimicrob Agents 
Chemother 2005; 49: 1857-64. 
[38] McAleese F, Petersen P, Ruzin A, et al. A novel MATE family 
efflux pump contributes to the reduced susceptibility of laboratory-
derived Staphylococus aureus mutants to tigecycline. Antimicrob 
Agents Chemother 2005; 49: 1865-71. 
[39] Huang J, O’Toole PW, Shen W, et al. Novel chromosomally en-
coded multidrug efflux transporter MdeA in Staphylococcus 
aureus. Antimicrob Agents Chemother 2004: 48: 909-17. 
[40] Yamada Y, Shiota S, Mizushima T, et al. Functional gene cloning 
and characterization of MdeA, a multidrug efflux pump from 
Staphylococcus aureus. Biol Pharm Bull 2006; 29: 801-4. 
[41] Narui K, Noguchi N, Wakasugi K, et al. Cloning and characteriza-
tion of a novel chromosomal drug efflux gene in Staphylococcus 
aureus. Biol Pharm Bull 2002; 25: 1533-6. 
[42] Yamada Y, Hideka K-I, Shiota S, et al. Gene cloning and charac-
terization of SdrM, a chromosomally-encoded multidrug efflux 
pump, from Staphylococcus aureus. Biol Pharm Bull 2006; 29: 
554-6. 
[43] Floyd JL, Smith KP, Kumar SH, et al. LmrS is a multidrug efflux 
pump of the Major Facilitator Superfamily from Staphylococcus 
aureus. Antimicrob Agents Chemother 2010; 54: 5406-12. 
[44] Tennent JM, Lyon BR, Gillespie MT, et al. Cloning and expression 
of Staphylococcus aureus plasmid-mediated quaternary ammonium 
resistance in Escherichia coli. Antimicrob Agents Chemother 1985; 
27: 79-83. 
MDR Efflux Pumps in Staphylococcus aureus The Open Microbiology Journal, 2013, Volume 7    69 
[45] Rouch DA, Cram DS, DiBerardino D, et al. Efflux-mediated anti-
septic resistance gene qacA from Staphylococcus aureus: common 
ancestry with tetracycline- and sugar-transport proteins. Mol Mi-
crobiol 1990; 4: 2051-62. 
[46] Leelaporn A, Paulsen IT, Tennent JM, et al. Multidrug resistance to 
antiseptics and disinfectants in coagulase-negative staphylococci. J 
Med Microbiol 1994; 40: 214-20. 
[47] Tennent JM, Lyon BR, Midgley M, et al. Physical and biochemical 
characterization of the qacA gene encoding antiseptic and disinfec-
tant resistance in Staphylococcus aureus. J Gen Microbiol 1989; 
135:1-10. 
[48] Mitchell BA, Brown MH, Skurray RA. QacA multidrug efflux 
pump from Staphylococcus aureus: comparative analysis of resis-
tance to diamidines, biguanidines, and guanylhydrazones. Antim-
icrob Agents Chemother 1998; 42: 475-7. 
[49] Brown MH, Skurray RA. Staphylococcal multidrug efflux pump 
protein QacA. J Mol Microbiol Biotechnol 2001; 3: 163-70. 
[50] Mitchell BA, Paulsen IT, Brown MH, et al. Bioenergetics of the 
Staphylococcal multidrug export protein QacA. J Biol Chem 1999; 
274: 3541-8. 
[51] Paulsen IT, Brown MH, Skurray RA. Characterization of the earli-
est known Staphylococcus aureus plasmid encoding a multidrug ef-
flux system. J Bacteriol 1998; 180: 3477-9. 
[52] Lyon BR, Skurray R. Antimicrobial resistance of Staphylococcus 
aureus: genetic basis. Microbiol Rev 1987; 51: 88-134. 
[53] Paulsen IT, Brown MH, Littlejohn TG, et al. Multidrug resistance 
proteins QacA and QacB from Staphylococcus aureus: membrane 
topology and identification of residues involved in substrate speci-
ficity. Proc Natl Acad Sci USA 1996; 93: 3630-5. 
[54] Xu Z, O’Rourke BA, Skurray RA, et al. Role of transmembrane 
segment 10 in efflux mediated by the staphylococcal multidrug 
transport protein QacA. J Biol Chem 2006; 281: 792-9. 
[55] Alam MM, Kobayashi N, Uehara N, et al. Analysis on distribution 
and genomic diversity of high-level antiseptic resistance genes 
qacA and qacB in human clinical isolates of Staphylococcus 
aureus. Microb Drug Resist 2003; 9: 109-21. 
[56] Nakaminami H, Noguchi N, Sasatsu M. Fluoroquinolone efflux by 
the plasmid-mediated multidrug efflux pump QacB variant QacBIII 
in Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54: 
4107-11. 
[57] Sasatsu M, Shima K, Shibata Y, et al. Nucleotide sequence of a 
gene that encodes resistance to ethidium bromide from a transfer-
able plasmid in Staphylococcus aureus. Nucleic Acids Res 1989; 
17: 10103. 
[58] Littlejohn TG, DiBerardino D, Messerotti LJ, et al. Structure and 
evolution of a family of genes encoding antiseptic and disinfectant 
resistance in Staphylococcus aureus. Gene 1991; 101: 59-66. 
[59] Grinius L, Dreguniene G, Goldberg EB, et al. A staphylococcal 
multidrug resistance gene product is a member of a new protein 
family. Plasmid 1992; 27: 119-29. 
[60] Leelaporn A, Firth N, Paulsen IT, et al. Multidrug resistance plas-
mid pSK108 from coagulase-negative staphylococci; relationships 
to Staphylococcus aureus qacC plasmids. Plasmid 1995; 34: 62-7. 
[61] Grinius LL, Goldberg EB. Bacterial multidrug resistance is due to a 
single membrane protein which functions as a drug pump. J Biol 
Chem 1994; 269: 29998-30004. 
[62] Paulsen IT, Brown MH, Dunstan SJ, et al. Molecular characteriza-
tion of the staphylococcal multidrug resistance export protein 
QacC. J Bacteriol 1995; 177: 2827-33. 
[63] Bay DC, Rommens KL, Turner RJ. Small multidrug resistance 
proteins: a multidrug transporter family that continues to grow. 
Biochim Biophys Acta 2008; 1778: 1814-38. 
[64] Heir E, Sundheim G, Holck AL. Resistance to quaternary ammo-
nium compounds in Staphylococcus spp. isolated from the food in-
dustry and nucleotide sequence of the resistance plasmid pST827. J 
Appl Bacteriol 1995; 79: 149-56. 
[65] Bjorland J, Sunde M, Waage S. Plasmid-borne smr gene causes 
resistance to quaternary ammonium compounds in bovine Staphy-
lococcus aureus. J Clin Microbiol 2001; 39: 3999-4004.  
[66] Alam MM, Ishino M, Kobayashi N. Analysis of genomic diversity 
and evolution of the low-level antiseptic resistance gene smr in 
Staphylococcus aureus. Microb Drug Resist 2003; 9(S1): S1-7.  
[67] Heir E, Sundheim G, Holck AL. The qacG gene on plasmid pST94 
confers resistance to quaternary ammonium compounds in staphy-
lococci isolates from the food industry. J Appl Microbiol 1999; 86: 
378-88. 
[68] Heir E, Sundheim G, Holck AL. The Staphylococcus qacH gene 
product: a new member of the SMR family encoding multidrug re-
sistance. FEMS Microbiol Lett 1998; 163: 49-56. 
[69] Bjorland J, Steinum T, Sunde M, et al. Novel plasmid-borne gene 
qacJ mediates resistance to quaternary ammonium compounds in 
equine Staphylococcus aureus, Staphylococcus simulans, and 
Staphylococcus intermedius. Antimicrob Agents Chemother 2003; 
47: 3046-52. 
[70] Fournier B, Aras R, Hooper DC. Expression of the multidrug resis-
tance transporter NorA from Staphylococcus aureus is modified by 
a two-component regulatory system. J Bacteriol 2000; 182: 664-71. 
[71] Luong TT, Newell SW, Lee CY. mgr, a novel global regulator in 
Staphylococcus aureus. J Bacteriol 2003; 185: 3703-10. 
[72] Ingavale S, van Wamel W, Cheung AL. Characterization of RAT, 
an autolysis regulator in Staphylococcus aureus. Mol Microbiol 
2003; 48: 1451-66. 
[73] Chen PR, Bae T, Williams WA, et al. An oxidation-sensing 
mechanism is used by the global regulator MgrA in Staphylococcus 
aureus. Nat Chem Biol 2006; 2: 591-5. 
[74] Ingavale S, van Wamel W, Luong TT, et al. Rat/MgrA, a regulator 
of virulence genes in Staphylococcus aureus. Infect Immun 2005; 
73: 1423-31. 
[75] Luong TT, Dunman PM, Murphy E, et al. Transcription profiling 
of the mgrA regulon in Staphylococcus aureus. J Bacteriol 2006; 
188: 1899-910. 
[76] Cheung AL, Nishina KA, Trotonda MP, et al. The SarA protein 
family of Staphylococcus aureus. Int J Biochem Cell Biol 2008; 
40: 355-61. 
[77] Gertz S, Engelmann S, Schmid R, et al. Characterization of the B 
regulon in Staphylococcus aureus. J Bacteriol 2000; 182: 6983-91. 
[78] Bischoff M, Dunman P, Kormanec J, et al. Microarray-based 
analysis of the Staphylococcus aureus B regulon. J Bacteriol 2004; 
186: 4085-99. 
[79] Truong-Bolduc QC, Zhang X, Hooper DC. Characterization of 
NorR protein, a multifunctional regulator of norA expression in 
Staphylococcus aureus. J Bacteriol 2003; 185: 3127-38. 
[80] Truong-Bolduc QC, Hooper DC. The transcriptional regulators 
NorG and MgrA modulate resistance to both quinolones and β-
lactams in Staphylococcus aureus. J Bacteriol 2007; 189: 2996-
3005. 
[81] Truong-Bolduc QC, Ding Y, Hooper DC. Posttranslational modifi-
cation influences the effects of MgrA on norA expression in 
Staphylococcus aureus. J Bacteriol 2008; 190: 7375-81. 
[82] Truong-Bolduc QC, Hooper DC. Phosphorylation of MgrA and its 
effect on expression of the NorA and NorB efflux pumps of 
Staphylococcus aureus. J Bacteriol 2010; 192: 2525-34. 
[83] Chen PR, Nishida S, Poor CB, et al. A new oxidative sensing and 
regulation pathway mediated by the MgrA homologue SarZ in 
Staphylococcus aureus. Mol Microbiol 2008; 71: 198-211. 
[84] Kosmidis C, DeMarco C, Frempong-Manso E, et al. In silico corre-
lations of multidrug efflux pump gene expression in Staphylococ-
cus aureus. Int J Antimicrob Agents 2010; 36: 222-9. 
[85] Fournier B, Hooper DC. A new two-component regulatory system 
involved in adhesion, autolysis and extracellular proteolytic activity 
of Staphylococcus aureus. J Bacteriol 2000; 182: 3955-64. 
[86] Liang X, Zheng L, Landwehr C, et al. Global regulation of gene 
expression by ArlRS, a two-component signal transduction regula-
tory system of Staphylococcus aureus. J Bacteriol 2005; 187: 5486-
92. 
[87] Deng X, Ji Q, Liang H, et al. Expression of multidrug resistance 
efflux pump gene norA is iron responsive in Staphylococcus 
aureus. J Bacteriol 2012; 194: 1753-62. 
[88] Kaatz GW, DeMarco CE, Seo SM. MepR, a repressor of the 
Staphylococcus aureus MATE family multidrug efflux pump 
MepA, is a substrate-responsive regulatory protein. Antimicrob 
Agents Chemother 2006; 50: 1276-81. 
[89] Kumaraswami M, Schuman JT, Seo SM, et al. Structural and bio-
chemical characterization of MepR, a multidrug binding transcrip-
tion regulator of the Staphyloocccus aureus multidrug efflux pump 
MepA. Nucleic Acids Res 2009; 37: 1211-24. 
[90] Opperman TJ, Williams JD, Houseweart C, et al. Efflux-mediated 
bis-indole resistance in Staphylococcus aureus reveals differential 
substrate specificities for MepA and MepR. Bioorg Med Chem 
2010; 18: 2123-30. 
70    The Open Microbiology Journal, 2013, Volume 7 Costa et al. 
[91] Grkovic S, Brown MH, Roberts NJ, et al. QacR is a repressor pro-
tein that regulates expression of the Staphylococcus aureus mul-
tidrug efflux pump QacA. J Biol Chem 1998; 273: 18665-73. 
[92] Grkovic S, Brown MH, Schumacher MA, et al. The staphylococcal 
QacR multidrug regulator binds a correctly spaced operator as a 
pair of dimers. J Bacteriol 2001; 183: 7102-9. 
[93] Schumacher MA, Miller MC, Grkovic S, et al. Structural basis for 
cooperative DNA binding by two dimers of the multidrug-binding 
protein QacR. EMBO J 2002; 21: 1210-8. 
[94] Schumacher MA, Miller MC, Grkovic S, et al. Structural mecha-
nisms of QacR induction and multidrug recognition. Science 2001; 
294: 2158-63. 
[95] Grkovic S, Hardie KM, Brown MH, et al. Interactions of the QacR 
multidrug-binding protein with structurally diverse ligands: impli-
cations for the evolution of the binding pocket. Biochemistry 2003; 
42: 15226-36. 
[96] Schmitz F-J, Fluit AC, Lückefahr M, et al. The effect of reserpine, 
an inhibitor of multidrug efflux pumps, on the in-vitro activities of 
ciprofloxacin, sparfloxacin and moxifloxacin against clinical iso-
lates of Staphylococcus aureus. J Antimicrob Chemother 1998; 42: 
807-10. 
[97] Muñoz-Bellido JL, Manzanares MAA, Martínez JÁ, et al. Efflux 
pump-mediated quinolones resistance in Staphylococcus aureus 
strains wild-type for gyrA, gyrB, grlA, and norA. Antimicrob 
Agents Chemother 1999; 43: 354-6. 
[98] Noguchi N, Okihara T, Namiki Y, et al. Susceptibility and resis-
tance genes to fluoroquinolones in methicillin-resistant Staphylo-
coccus aureus isolated in 2002. Int J Antimicrob Agents 2005; 25: 
374-9. 
[99] Lomovskaya O, Waltkins W. Inhibition of efflux pumps as a novel 
approach to combat drug resistance in bacteria. J Mol Microbiol 
Biotechnol. 2001; 3: 225-36. 
[100] Amaral L, Viveiros M, Kristiansen JE. "Non-Antibiotics": alterna-
tive therapy for the management of MDRTB and MRSA in eco-
nomically disadvantaged countries. Curr Drug Targets 2006; 7: 
887-91.  
[101] Marquez B. Bacterial efflux systems and efflux pump inhibitors. 
Biochimie 2005; 87: 1137-47. 
[102] Frempong-Manso E, Raygada JL, DeMarco CE, et al. Inability of a 
reserpine-based screen to identify strains overexpressing efflux 
pump genes in clinical isolates of Staphylococcus aureus. Int J An-
timicrob Agents 2009; 33: 360-3.  
[103] Pagès JM, Amaral L. Mechanisms of drug efflux and strategies to 
combat them: challenging the efflux pump of Gram-negative bacte-
ria. Biochim Biophys Acta 2009; 1794: 826-33.  
[104] Patel D, Kosmidis C, Seo SM, et al. Ethidium bromide MIC 
screening for enhanced efflux pump gene expression or efflux ac-
tivity in Staphylococcus aureus. Antimicrob Agents Chemother 
2010; 54: 5070-3. 
[105] Costa SS, Falcão C, Viveiros M, et al. Exploring the contribution 
of efflux on the resistance to fluoroquinolones in clinical isolates of 
Staphylococcus aureus. BMC Microbiol 2011; 11: e241. 
[106] Martins M, Viveiros M, Couto I, et al. Identification of efflux 
pump-mediated multidrug-resistant bacteria by the Ethidium Bro-
mide-Agar Cartwheel Method. In Vivo 2011; 25: 171–8. 
[107] Viveiros M, Rodrigues L, Martins M, et al. Antibiotic Resistance 
Protocols. In: Gillespie SH, McHugh TD, Eds. Evaluation of efflux 
activity of bacteria by a semi-automated fluorometric system. New 
York: Humana Press 2010; pp. 159-72.  
[108] Poole K. Efflux pumps as antimicrobial resistance mechanisms. 
Ann Med 2007 39: pp. 162-76. 
[109] Ferrero L, Cameron B, Crouzet J. Analysis of gyrA and grlA muta-
tions in stepwise-selected ciprofloxacin-resistant mutants of 
Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 
1554-8. 
[110] Ng EY, Trucksis M, Hooper DC. Quinolone resistance mutations in 
topoisomerase IV: relationship to the flqA locus and genetic evi-
dence that topoisomerase IV is the primary target and DNA gyrase 
is the secondary target of fluoroquinolones in Staphylococcus 
aureus. Antimicrob Agents Chemother 1996; 40: 1881-8. 
[111] Hooper DC. Mechanisms of fluoroquinolone resistance. Drug 
Resist Updat 1999; 2: 38-55. 
[112] Tanaka M, Zhang YX, Ishida H, et al. Mechanisms of 4-quinolone 
resistance in quinolones-resistant and methicillin-resistant Staphy-
lococcus aureus isolates from Japan and China. J Med Microbiol 
1995; 42: 214-9. 
[113] Schmitz F-J, Köhrer K, Scheuring S, et al. The stability of grlA, 
grlB, gyrA, gyrB and norA mutations and MIC values of five 
fluoroquinolones in three different clonal populations of methicil-
lin-resistant Staphylococcus aureus. Clin Microbiol Infect 1999; 5: 
287-90. 
[114] Schmitz F-J, Fluit AC, Brisse S, et al. Molecular epidemiology of 
quinolones resistance and comparative in vitro activities of new 
quinolones against European Staphylococcus aureus isolates. 
FEMS Immunol Med Microbiol 1999; 26: 281-7. 
[115] Guirao GY, Toldos MCM, Peris BM, et al. Molecular diversity of 
quinolones resistance in genetically related clinical isolates of 
Staphylococcus aureus and susceptibility to newer quinolones. J 
Antimicrob Chemother 2001; 47: 157-61. 
[116] Horii T, Suzuki Y, Morita M, et al. Detection of mutations in qui-
nolone resistance-determining regions in levofloxacin- and methi-
cillin-resistant Staphylococcus aureus: effects of the mutations on 
fluoroquinolone MICs. Diagn Microbiol Infect Dis 2003; 46: 139-
45. 
[117] Hernández A, Sánchez MB, Martínez JL. Quinolone resistance: 
much more than predicted. Front Microbiol 2011; 2: e22. 
[118] SCENIHR (Scientific Committee on Emerging and Newly Identi-
fied Health Risks), Assessment of the Antibiotic Resistance Effects 
of Biocides [Accessed on: 19 January 2009] Available on http:// 
ec.eropa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_
021.pdf 
[119] Chaplin CE. Bacterial resistance to quaternary ammonium disinfec-
tants. J Bacteriol 1951; 63: 453-8. 
[120] Russell AD. Introduction of biocides into clinical practice and the 
impact on antibiotic-resistant bacteria. J Appl Microbiol 2002; 92: 
121S-35. 
[121] Weber DJ, Rutala WA, Sickbert-Bennett EE. Outbreaks associated 
with contaminated antiseptics and disinfectants. Antimicrob Agents 
Chemother 2007; 51: 4217-24. 
[122] Buffet-Bataillon S, Tattevin P, Bonnaure-Mallet M, et al. Emer-
gence of resistance to antibacterial agents: the role of quaternary 
ammonium compounds-a critical review. Int J Antimicrob Agents 
2012; 39: 381-9. 
[123] Noguchi N, Suwa J, Narui K, et al. Susceptibilities to antiseptics 
and distribution of antiseptic-resistance genes qacA/B and smr of 
methicillin-resistance Staphylococcus aureus isolated in Asia dur-
ing 1998 and 1999. J Med Microbiol 2005; 54: 557-65. 
[124] Sheng W-H, Wang J-T, Lauderdale T-L, et al. Epidemiology and 
susceptibilities of methicillin-resistant Staphylococcus aureus in 
Taiwan: emphasis on chlorhexidine susceptibility. Diagn Microbiol 
Infect Dis 2009; 63: 309-13. 
[125] Sekiguchi J-I, Hama T, Fujino T, et al. Detection of the antiseptic- 
and disinfectant-resistance genes qacA, qacB, and qacC in methi-
cillin-resistant Staphylococcus aureus isolated in a Tokyo hospital. 
Jpn J Infect Dis 2004; 57: 288-91. 
[126] Noguchi N, Nakaminami H, Nishijima S, et al. Antimicrobial agent 
of susceptibilities and antiseptic resistance gene distribution among 
methicillin-resistant Staphylococcus aureus isolates from patients 
with impetigo and staphylococcal scalded skin syndrome. J Clin 
Microbiol 2006; 44: 2119-25. 
[127] Mayer S, Boos M, Beyer A, et al. Distribution of the antiseptic 
resistance genes qacA, qacB, and qacC in 497 methicillin-resistant 
and -susceptible European isolates of Staphylococcus aureus. J An-
timicrob Chemother 2001; 47: 893-5. 
[128] Vali L, Davies SE, Lai LLG, et al. Frequency of biocide resistance 
genes, antibiotic resistance and the effect of chlorhexidine exposure 
on clinical methicillin-resistant Staphylococcus aureus isolates. J 
Antimicrob Chemother 2008; 61: 524-32. 
[129] Smith K, Gemmell CG, Hunter IS. The association between biocide 
tolerance and the presence or absence of qac genes among hospital-
acquired and community-acquired MRSA isolates. J Antimicrob 
Chemother 2008; 61: 78-84.  
[130] Zmantar T, Kouidhi B, Miladi H, et al. Detection of macrolide and 
disinfectant resistance genes in clinical Staphylococcus aureus and 
coagulase-negative staphylococci. BMC Res Notes 2011; 4: e453. 
[131] Longtin J, Seah C, Siebert K, et al. Distribution of antiseptic resis-
tance genes qacA, qacB, and smr in methicillin-resistant Staphylo-
coccus aureus isolated in Toronto, Canada, from 2005 to 2009. An-
timicrob Agents Chemother 2011; 55: 2999-3001. 
[132] Bjorland J, Steinum T, Kvitle B, et al. Widespread distribution of 
disinfectant resistance genes among staphylococci of bovine and 
caprine origin in Norway. J Clin Microbiol 2005; 43: 4363-8. 
MDR Efflux Pumps in Staphylococcus aureus The Open Microbiology Journal, 2013, Volume 7    71 
[133] Ye M-F, Zhang M, O’Donoghue M, et al. Are qacG, qacH and 
qacJ genes transferring from food isolates to carriage isolates of 
staphylococci? J Hosp Infect 2012; 80: 95-6. 
[134] Costa SS, Ntokou E, Martins A, et al. Identification of the plasmid-
encoded qacA efflux pump gene in meticillin-resistant Staphylo-
coccus aureus (MRSA) strain HPV107, a representative of the 
MRSA Iberian clone. Int J Antimicrob Agents 2010; 36: 557-61. 
[135] Maillard J-Y. Bacterial resistance to biocides in the healthcare 
environment: should it be of genuine concern? J Hosp Infect 2007; 
65: 60-72. 
[136] Meyer B, Cookson B. Does microbial resistance or adaptation to 
biocides create a hazard in infection prevention and control? J Hosp 
Infect 2010; 76: 200-5. 
[137] Suller MTE, Russell AD. Antibiotic and biocide resistance in me-
thicillin-resistant Staphylococcus aureus and vancomycin-resistant 
enterococcus. J Hosp Infect 1999; 43: 281-91. 
[138] Walsh SE, Maillard J-Y, Russell AD, et al. Development of bacte-
rial resistance to several biocides and effects on antibiotic suscepti-
bility. J Hosp Infect 2003; 55: 98-107. 
[139] Narui K, Takano M, Noguchi N, et al. Susceptibilities of methicil-
lin-resistant Staphylococcus aureus isolates to seven biocides. Biol 
Pharm Bull 2007; 30: 585-7. 
[140] Thorrold CA, Letsoalo ME, Dusé AG, et al. Efflux pump activity 
in fluoroquinolone and tetracycline resistant Salmonella and E. coli 
implicated in reduced susceptibility to household antimicrobial 
cleaning agents. Int J Food Microbiol 2007; 113: 315-20. 
[141] Wootton M, Walsh TR, Davies EM, et al. Evaluation of the effec-
tiveness of common hospital hand disinfectants against methicillin-
resistant Staphylococcus aureus, glycopeptides-intermediate S. 
aureus, and heterogeneous glycopeptides-intermediate S. aureus. 
Infect Control Hosp Epidemiol 2009; 30: 226-32. 
[142] Anthonisen I-L, Sunde M, Steinum TM, et al. Organization of the 
antiseptic resistance gene qacA and Tn552-related β-lactamase 
genes in multidrug-resistant Staphylococcus haemolyticus strains of 
animal and human origins. Antimicrob Agents Chemother 2002; 
46: 3606-12. 
[143] Sidhu MS, Heir E, Leegaard T, et al. Frequency of disinfectant 
resistance genes and genetic linkage with β-lactamase transposon 
Tn552 among clinical staphylococci. Antimicrob Agents Chemo-
ther. 2002; 46: 2797-803. 
[144] Jensen SO, Apisiridej S, Kwong SM, et al. Analysis of the proto-
typical Staphylococcus aureus multiresistance plasmid pSK1. 
Plasmid 2010; 64: 135-42. 
[145] Berg T, Firth N, Apisiridej S, et al. Complete nucleotide sequence 
of pSK41: evolution of staphylococcal conjugative multiresistance 
plasmids. J Bacteriol 1998; 180: 4350-9. 
[146] Nakaminami H, Noguchi N, Nishijima S, et al. Characterization of 
the pTZ2162 encoding multidrug efflux gene qacB from Staphylo-
coccus aureus. Plasmid 2008; 60: 108-17. 
[147] Lambert RJW. Comparative analysis of antibiotic and antimicrobial 
biocide susceptibility data in clinical isolates of methicillin-
sensitive Staphylococcus aureus, methicillin-resistant Staphylococ-
cus aureus and Pseudomonas aeruginosa between 1989 and 2000. 
J Appl Microbiol 2004; 97: 699-711. 
[148] Zhang M, O’Donoghue MM, Ito T, et al. Prevalence of antiseptic-
resistance genes in Staphylococcus aureus and coagulase-negative 
staphylococci colonizing nurses and the general population in Hong 
Kong. J Hosp Infect 2011; 78: 113-8. 
[149] Singh R, Swick MC, Ledesma KR, et al. Temporal interplay be-
tween efflux pumps and target mutations in development of  
antibiotic resistance in Escherichia coli. Antimicrob Agents 
Chemother 2012; 56: 1680-5. 
[150] Machado D, Couto I, Perdigão J, et al. Contribution of efflux to the 
emergence of isoniazid and multidrug resistance in Mycobacterium 
tuberculosis. PLoS ONE 2012; 7: e34538. 
[151] Markham PN, Neyfakh AA. Inhibition of the multidrug transporter 
NorA prevents emergence of norfloxacin resistance in Staphylo-
coccus aureus. Antimicrob Agents Chemother 1996; 40: 2673-4. 
[152] Sulavik MC, Barg NL. Examination of methicillin-resistant and 
methicillin-susceptible Staphylococcus aureus mutants with low-
level fluoroquinolone resistance. Antimicrob Agents Chemother 
1998; 42: 3317-9. 
 
 
Received: December 01, 2012 Revised: January 24, 2013 Accepted: January 25, 2013 
 
© Costa et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ 
by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.  
 
